Homozygous familial hypercholesterolemia with an update on cholesterol management

Anju J. J. Velvet1, Handrean Soran2, Bernard Clarke1, Manish Motwani1, Farzin F. Ordoubadi1 and Matthew J. Daniels1,3,4, *

1Manchester Heart Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK, 2Department of Endocrinology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK, 3Division of Cardiovascular Sciences, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK, 4Division of Cell Matrix Biology and Regenerative Medicine, University of Manchester, Manchester, UK

© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Abstract

Familial hypercholesterolemia (FH) is an autosomal dominant condition that increases the risk of premature cardiovascular disease. Despite advances in treatment, it remains under detected and under treated. As an inherited condition, it poses a risk to the patient and family members. Most cases are due to defective low-density lipoprotein receptor (LDLR) activity. Heterozygous mutations are common (1:250–1:300). Homozygous FH is very rare (2–3 in a million), with higher circulating cholesterol levels and a poorer cardiovascular prognosis. We present the management of a case of homozygous hypercholesterolemia due to homozygous LDLR mutation. The patient subsequently developed severe coronary artery and aortic valve disease despite aggressive lipid-lowering therapy. We review advanced lipid management options that include lipoprotein apheresis, Proprotein Convertase Subtilisin/Kexin type 9 inhibition, and the microsomal triglyceride transfer protein inhibitor lomitapide.

INTRODUCTION

In familial hypercholesterolemia (FH), increased low-density lipoprotein cholesterol (LDL-C) accelerates atherosclerotic cardiovascular disease (ACVD). Most commonly this is caused by mutations in the low-density lipoprotein receptor (LDLR) gene, but rarely (~5% of cases) mutations in Apolipoprotein B-100 (APO-B), the ligand for LDLR, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), Apolipoprotein E or LDLR adaptor protein genes are responsible. We present a rare case of extreme hypercholesterolaemia due to homozygous mutation in LDLR, complicated by multi-vessel coronary artery disease (CAD) and aortic stenosis (AS).
Management of familial hypercholesterolemia

Figure 1: Pathognomonic signs of FH: tendon xanthoma deposits of cholesterol rich fat on the dorsum of both hands and knees.

died aged 82 and his mother aged 90. His three siblings have no known ACVD. Mandatory cascade testing showed high LDL levels in all six daughters with heterozygous FH (HeFH) status in all children. He has a history of hypertension managed on three agents. He worked as a teacher and does not drink alcohol or smoke. His lipid-lowering interventions are summarized in (Fig. 2). Although LDL apheresis produced an ~83% reduction in LDL-C immediately after apheresis, LDL-C levels returned to baseline within days, and interval mean LDL-C remained high. Multiple interruptions to LDL-apheresis occurred due to arteriovenous fistula failure, which ultimately occluded after 18 months.

Cardiac computed tomography (CT) to screen for ACVD, confirmed multi-vessel CAD with extensive calcification of the ascending aorta, aortic valve, and posterior mitral annulus (Fig. 3). Echocardiography confirmed severe AS (valve area: 0.5 cm²). Due to the hostile aortic root precluding coronary artery bypass grafting, transcatheter aortic valve implantation and percutaneous coronary intervention were recommended.

DISCUSSION

Anichkov first demonstrated the role of high cholesterol in atherosclerosis in 1913 [1]. Subsequently, the molecular basis of hypercholesterolemia has been determined [2]. HeFH is the most common inherited cardiovascular disorder (prevalence of 1:250–300), increasing premature ACVD risk ~20-fold [2]. HoFH is very rare and life threatening. Characterized by > 4-fold increase in LDL-C from birth, the first major cardiovascular event is frequently in adolescence but occasionally early childhood [3]. Early diagnosis and treatment improve clinical outcomes.

European Society of Cardiology (ESC) guidelines emphasize a goal-targeted approach to reduce LDL-C for very high cardiovascular disease (CVD) risk patients [4]. Hyperlipidemia Education and Atherosclerosis Research Trust in the UK recommends an LDL-C target of 1.8 mmol/L and 2.5 mmol/L for HoFH patients with, and without, ACVD respectively. Patients may fail to reach desired targets despite aggressive treatment, here the aim to achieve the maximum reduction with minimum side effects [3, 4]. Persistent hypercholesterolemia despite combination triple therapy (statin, ezetimibe and fenofibrate) triggers specialist lipid clinic referral.

Colesevelam, a bile acid sequestrant, which typically achieves ~16% LDL-C reduction, was tried but discontinued due to gastrointestinal side effects. LDL-C remained high, fulfilling criteria for LDL-apheresis.

LDL-apheresis, although not widely available, is highly effective at LDL removal (by 50–70%) from plasma, reducing cardiovascular events by 80–90% [2]. However, target interval LDL-C levels may not be achieved despite immediate post-treatment reduction. For example, our patient’s interval LDL-C values were 11.8 mmol/l with LDL apheresis every 2 weeks.

PCSK9 inhibitors are monoclonal antibodies inhibiting degradation of LDLR, thus increasing cholesterol clearance by hepatocytes [2]. Two Food and Drug Administration-approved PCSK9 inhibitors, alirocumab and evolocumab, are given as injections every 2–4 weeks [2]. Evolocumab reduces LDL-C in HoFH patients
with or without lipoprotein apheresis (Trial Assessing Long Term Use of PCSK9 Inhibition in Subjects With Genetic LDL Disorders study) accompanied by a reduction in cardiovascular events [5]. However, the addition of PCSK9 inhibition [420 mg injections fortnightly] was ineffective in our patient (~1% LDL reduction). This may be related to the complex spectrum of consequences of the Pro685Leu mutation, which in functional assays include defective processing, accelerated turnover, reduced cell surface expression and impaired LDLR activity [6–9]. Therefore, lomitapide [5 mg ON] was added to the medication regime.

Lomitapide is a microsomal triglyceride transfer protein inhibitor that reduces plasma levels of all APO-B-containing lipoproteins. In our patient, this achieved a 54% reduction in LDL-C after 6 months of treatment (the most recent LDL-C is 8.33 mmol/l). Further dose escalation is planned. Phase II and III, single-arm studies in HoFH show dose-dependent LDL-C reductions between 25 and 51% [10]. An observational study showed a 15% reduction in major adverse cardiovascular events for every 1 mmol/L LDL-C reduction [2]. The monitoring of transaminases is necessary during lomitapide treatment due to increased hepatic fat [2].

Aside from the complexities of this patient’s lipid management, it is notable that significant cardiovascular complications have arisen in the absence of symptoms. CVD risk assessment tools developed for the general population do not apply to FH patients as the atherosclerotic burden from long-term exposure to high LDL levels is underestimated [2].

CONCLUSION
HoFH is a very rare severe genetic disorder with cholesterol levels >4-fold normal from birth. Given the increased ACVD risk patients require a multi-agency approach to their care and regular screening for cardiovascular complications.

ACKNOWLEDGEMENTS
None.

Conflict of interest statement. None declared.

FUNDING
No funding was obtained for this report.

ETHICAL APPROVAL
Standards with respect to publication ethics have been observed.

CONSENT
The patient provides formal written consent to publication of medical photography.

GUARANTOR
Matthew Daniels accepts official responsibility for the overall integrity of the manuscript and attests that all statements in the manuscript are true to his knowledge.

REFERENCES
1. Konstantinov IE, Mejjevoi N, Anichkov NM, Nikolai N. Anichkov and his theory of atherosclerosis. Tex Heart Inst J 2006;33:417–23.
2. Mytilinaiou M, Kyrou I, Khan M, Grammatopoulos DK, Randeva HS. Familial hypercholesterolemia: new horizons for diagnosis and effective management. Front Pharmacol 2018;9:707. doi: 10.3389/fphar.2018.00707.
3. France M, Rees A, Datta D, Thompson G, Capps N, Ferns G, et al. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis 2016;255:128–39. doi: 10.1016/j.atherosclerosis.2016.10.017.
4. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111–88. doi: 10.1093/eurheartj/ehz455.
5. Raal FJ, Hovingh KG, Blom D, Santos RD, Harada-Shiba M, Bruckert E, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. *Lancet Diabetes Endocrinol* 2017;5:280–90. doi: 10.1016/S2213-8587(17)30044-X.

6. Rubinsztein DC, Coetzee GA, Marais AD, Leitersdorf E, Seftel HC, van der Westhuyzen DR. Identification and properties of the proline664-leucine mutant LDL receptor in south Africans of Indian origin. *J Lipid Res* 1992;33:1647–55.

7. Thormaehlen AS, Schuberth C, Won H-H, Blattmann P, Joggerst-Thomalla B, Theiss S, et al. Systematic cell-based phenotyping of missense alleles empowers rare variant association studies: a case for LDLR and myocardial infarction. *PLoS Genet* 2015;11:e1004855. doi: 10.1371/journal.pgen.1004855.

8. Knight BL, Gavigan SJ, Soutar AK, Patel DD. Defective processing and binding of low-density lipoprotein receptors in fibroblasts from a familial hypercholesterolaemic subject. *Eur J Biochem* 1989;179:693–8. doi: 10.1111/j.1432-1033.1989.tb14602.x.

9. Knight BL, Patel DD, Soutar AK. Regulation of synthesis and cell content of the low-density-lipoprotein receptor protein in cultured fibroblasts from normal and familial hypercholesterolaemic subjects. *Eur J Biochem* 1987;163:189–96. doi: 10.1111/j.1432-1033.1987.tb10754.x.

10. Alonso R, Cuevas A, Mata P. Lomitapide: a review of its clinical use, efficacy, and tolerability. *Core Evid* 2019;14:19–30. doi: 10.2147/CE.S174169.